BMI Vaccine Breakthrough Promises Polio-free World: ultraIPVTM


Biological Mimetics, Inc., a vaccine design company based in Frederick, MD, has announced their development of a next-generation polio vaccine that is safer, more potent, and less expensive to manufacture than current polio vaccines in an effort to boost eradication. 

The polio vaccine has been one of the major medical success stories as the incidence of poliomyelitis has been eliminated in almost all countries and global eradication appears close at hand.  Polio serotypes 2 and 3 have been successfully eradicated and efforts to eliminate Polio 1 are continuing. Once eradicated, the current vaccines will need modernization to maintain a polio-free world. The Oral Poliovirus Vaccine (OPV) is an inexpensive and effective vaccine and has been the workhorse of eradication efforts. However, the attenuated strains of OPV can revert to pathogenic forms and this vaccine has been phased out in most countries in favor of the Inactivated Poliovirus Vaccine (IPV) which is a killed-virus, injectable vaccine. As eradication progresses, the biosafety and biosecurity concerns associated with current manufacturing of IPV from pathogenic strains will become increasingly serious.

Click here to read the full press release.

 BMI is a innov
ative, privately-held vaccine design and development company located in Frederick, Maryland, USA.
Contact Us     Email:      Phone: (301) 378-2551  Info: Download White Paper
Download our recent publication in PLOS ONE describing the inactivation of polio using gamma irradiation: Click here.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.